AstraZeneca hails ‘groundbreaking’ results of new breast cancer drug trial

- Advertisement -

AstraZeneca has announced that a new breast cancer drug reduces the risk of death or disease progression by up to 72 percent compared to existing treatments.

- Advertisement -

The British pharmaceutical firm said the results of Enhartu’s trial were “unprecedented” and showed “a strong trend towards improving overall survival”.

However AstraZeneca cautioned that the analysis is “not yet mature and not statistically significant”.


The phase 3 trial, which compared the performance of Enhertu against trastuzumab emtansine as a treatment for HER2-positive metastatic breast cancer, involved approximately 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America.

AstraZeneca said nearly all patients treated with Enhartu were alive after 12 months (94.1 percent), compared with 85.9 percent of patients treated with trastuzumab emtensin (T-DM1).

- Advertisement -

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, said: “Today’s results are unprecedented.

“These unprecedented data represent a potential paradigm shift in the treatment of HER2-positive metastatic breast cancer, and illustrate the potential of Enhertu To transform more patient lives in an earlier treatment setting. “

Javier Cortés of the International Breast Cancer Center in Barcelona said patients with previously treated HER2-positive metastatic breast cancer will experience disease progression in less than a year with commonly available HER2-directed treatments.

They noted that the “high and consistent benefit” seen in the efficacy endpoints and key subgroups of patients receiving EnHertu is remarkable and supports EnHertu’s potential to become the new standard of care for those who previously had HER2 -have been treated for a positive metastatic breast. cancer”.

Ken Takeshita, Global Head of R&D at Daiichi Sankyo, said: “These historical data will form the basis of our discussions with global health authorities to potentially give Enhartu more exposure to patients with previously treated HER2-positive metastatic breast cancer. to be introduced as an effective treatment option at the earliest.”

While breast cancer survival rates have doubled in the UK over the past four decades, around 11,500 women and 85 men die from the disease each year.

Additional reporting by agencies


Credit: /

- Advertisement -
Mail Us For  DMCA / Credit  Notice

Recent Articles

Stay on top - Get the daily news in your inbox

Related Stories